Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-09-28. The firm is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The firm has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The firm conducts its businesses within domestic and overseas markets.
최신 재무제표(Form-10K)에 따르면, Zai Lab Ltd의 총 자산은 $0이며, 순손실입니다.
ZLAB의 주요 재무 비율은 무엇인가요?
Zai Lab Ltd의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
Zai Lab Ltd의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Zai Lab Ltd 주요 수익원은 Innovative Therapies이며, 최신 수익 발표에서 수익은 3,587,394,608입니다. 지역별로는 Greater China and United States이 Zai Lab Ltd의 주요 시장이며, 수익은 3,587,394,608입니다.